Explore Stanford technologies available for licensing:

Researchers in the Ginzton lab at Stanford University have patented an all-dielectric laser-driven microstructure for producing controllable charged particle beam.

Stanford researchers have developed a highly specific, tunable system to improve the safety, efficacy and deliverability of gene therapy vectors and other biological therapies.

Researchers in Dr. Michael Cleary's laboratory at Stanford University have developed a highly specific monoclonal antibody for AF4, a proto-oncoprotein associated with pediatric and adult leukemia.

Researchers in Dr. Michael Cleary's laboratory at Stanford University have developed a highly specific monoclonal antibody for ENL, a proto-oncoprotein associated with pediatric and adult leukemia.

Proxy Identity Based Encryption (proxy IBE) is a new encryption scheme that allows a user to send data encrypted with any given public key to a receiving user who decrypts the data with their own private key which is of no relation to the key used for encryption.

A common dominant negative allele, Aldh2*2, exists in the human population.

Rat monoclonal antibody BZ194 specifically recognizes mouse serpentine receptor mCMKLR1 (aka ChemR23, DEZ). mCMKLR1 is a novel protein possessing high homology with members of the chemoattractant receptor family, and binds the chemoattractant chemerin.

A novel design for a cross-shape micromechanical resonator that consists of an array of devices suited for integrated single chip frequency references, filter, and sensors.

Stanford researchers in John Cioffi's lab have developed a method for allocating resources (bit rate and transmit power) in multi-user, multi-carrier communication systems. The invention provides the optimal power allocation algorithm for the equal-length DSL loops.

Stanford scientists in Dr. Liqun Luo's laboratory have developed a patented method for site-directed somatic cell recombination and concurrent labeling of "knock in" cells.

This invention is from the Pritzker Neuropsychiatric Disorders Research Consortium, a collaborative research enterprise comprised of several leading academic institutions and based on a long-term relationship between the Pritzker family and scientists at the various institutio

This invention is from the Pritzker Neuropsychiatric Disorders Research Consortium, a collaborative research enterprise comprised of several leading academic institutions and based on a long-term relationship between the Pritzker family and scientists at the various institutio

This invention is from the Pritzker Neuropsychiatric Disorders Research Consortium, a collaborative research enterprise comprised of several leading academic institutions and based on a long-term relationship between the Pritzker family and scientists at the various institutio

Researchers in the laboratory of Dr. Michael Cleary at Stanford University have developed anti-Pbx1b monoclonal antibodies to study transcriptional regulation, embryonic development, and tissue homeostasis.

Researchers in the laboratory of Dr. Michael Cleary at Stanford University have developed anti-Pbx2 monoclonal antibodies to study transcriptional regulation, embryonic development, and tissue homeostasis.